Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: Phase 3 study
Bibliographic record
Abstract
4508 Background: In earlier trials, atrasentan, a potent, selective, oral endothelin A receptor antagonist, significantly delays time to disease progression (TTP) in a per-protocol group of hormone-refractory prostate cancer (HRPC) patients identified pre–blind break. We report the results from a phase 3 trial. Methods: 809 subjects with metastatic HRPC enrolled into a phase 3, randomized, double-blind, placebo-controlled study of 10 mg atrasentan were analyzed (401 placebo, 408 atrasentan). Kaplan-Meier and Cox proportional hazard methodologies were used to compare TTP (a composite of radiographic and clinical measures) between treatments. Analysis of covariance compared change from baseline to final value in PSA and bone and total alkaline phosphatase (BAP and ALP). Data from a protocol-compliant subset identified prior to blind break were analyzed as well. Results: Atrasentan exhibited a nonsignificant trend in delayed TTP (log-rank p=0.091; hazard ratio [HR] = 1.14, 95% CI = 0.98–1.34) and significantly delayed time to BAP progression (TTBAP, >50% increase from nadir) versus placebo (median: 254 vs 505 days; log-rank p<0.001; HR = 1.78, 95% CI = 1.34–2.37). The atrasentan group showed smaller mean increases than the placebo group in PSA (p=0.025), BAP (p=0.001), and ALP (p<0.001). In the protocol-compliant subset (329 placebo, 342 atrasentan), atrasentan significantly delayed TTP (log-rank p=0.007; HR = 1.26, 95% CI = 1.06–1.50) and TTBAP (log-rank p<0.001) and resulted in smaller mean changes from baseline to final in the 3 biological markers. Atrasentan was well tolerated. The most common associated adverse events, peripheral edema, rhinitis, and headache, resulted in few discontinuations. Conclusions: Atrasentan demonstrated a significant delay in TTP and attenuated increase in relevant bone and tumor markers in metastatic HRPC patients representative of the intended target population. The accumulating and consistent data for atrasentan demonstrates biologic and clinical activity of endothelin receptor blockade in metastatic HRPC. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Abbott Laboratories Abbott Laboratories Abbott Laboratories Aventis Abbott Laboratories
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".